top of page

After a $93M series B, Character Bio's CEO Cheng Zhang describes how the company has built a proprietary database to reclassify AMD patients into genetic subgroups to optimize trial patient selection

  • blonca9
  • Apr 1, 2025
  • 1 min read

He describes why a 'one-size-fits-all' approach has caused numerous ophthalmology trials to fail in the past, and why Character believes a precision medicine approach is overdue.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page